Home  
  Our Team  
  Patient Info  
  Services  
   
  Pay My Bill  
  Contact Us  

News for Healthier Living

Patients with Large Territory STEMI and High Thrombus Burden Do Not Benefit from Intracoronary Delivery of Low-dose Fibrinolytics During PCI

Results from the multicenter, randomized, double-blind, placebo-controlled STRIVE trial found that low doses of recombinant tPA (alteplase) in patients with large-territory STEMI and high thrombus burden undergoing primary percutaneous coronary intervention (PCI) did not improve outcomes.

October 28, 2025


October 29 2025

October 28 2025

October 27 2025

October 26 2025

October 25 2025

October 24 2025

October 23 2025

October 22 2025

October 21 2025

October 20 2025

October 19 2025

October 18 2025

October 17 2025

October 16 2025

October 15 2025